Bristol-Myers Squibb (NYSE:BMY) Shares Up 0.1%

Bristol-Myers Squibb (NYSE:BMY - Get Free Report)'s share price rose 0.1% during mid-day trading on Monday . The stock traded as high as $45.38 and last traded at $44.90. Approximately 2,804,424 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 15,800,512 shares. The stock had previously closed at $44.85.

Wall Street Analyst Weigh In

BMY has been the subject of several research analyst reports. BMO Capital Markets lowered their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a "market perform" rating for the company in a report on Friday. Wells Fargo & Company increased their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an "equal weight" rating in a research note on Thursday, April 18th. Redburn Atlantic cut shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. StockNews.com cut shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Monday, April 15th. Finally, William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $60.00.

Bristol-Myers Squibb Price Performance

The stock's fifty day moving average price is $50.93 and its 200-day moving average price is $51.02. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The firm has a market cap of $90.51 billion, a PE ratio of -14.40, a P/E/G ratio of 15.47 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business's revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm posted $2.05 EPS. As a group, equities analysts forecast that Bristol-Myers Squibb will post 0.58 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 5.38%. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently -77.42%.

Hedge Funds Weigh In On Bristol-Myers Squibb

Several hedge funds have recently added to or reduced their stakes in BMY. Golden State Equity Partners increased its holdings in Bristol-Myers Squibb by 6.2% during the 3rd quarter. Golden State Equity Partners now owns 13,188 shares of the biopharmaceutical company's stock valued at $765,000 after acquiring an additional 765 shares in the last quarter. Avestar Capital LLC grew its holdings in shares of Bristol-Myers Squibb by 43.1% during the third quarter. Avestar Capital LLC now owns 5,706 shares of the biopharmaceutical company's stock worth $331,000 after buying an additional 1,719 shares in the last quarter. Brookstone Capital Management grew its holdings in shares of Bristol-Myers Squibb by 191.7% during the third quarter. Brookstone Capital Management now owns 95,503 shares of the biopharmaceutical company's stock worth $5,394,000 after buying an additional 62,766 shares in the last quarter. PDS Planning Inc grew its holdings in shares of Bristol-Myers Squibb by 7.4% during the third quarter. PDS Planning Inc now owns 8,219 shares of the biopharmaceutical company's stock worth $477,000 after buying an additional 563 shares in the last quarter. Finally, Compagnie Lombard Odier SCmA grew its holdings in shares of Bristol-Myers Squibb by 459.8% during the third quarter. Compagnie Lombard Odier SCmA now owns 2,435 shares of the biopharmaceutical company's stock worth $141,000 after buying an additional 2,000 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.